Senti Biosciences Holdings, Inc. (SNTI) stock
SNTINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.10−0.04 (-28.68%)
Close on Nov 17, 2026Market cap $3.02MP/E –Yield –
Earnings
Senti Biosciences's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Nov 12, 2026
Q3 FY2026 · estimated, after the close
Revenue, Q1 FY2026
$16.00K
EPS, Q1 FY2026
-$0.14
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Senti Biosciences's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q3 FY2026ended Sep 30, 2026 | Nov 12, 2026Expected | – | – | – | – |
| Q2 FY2026ended Jun 30, 2026 | Jul 15, 2026before the open | – | – | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 14, 2026before the open | $16.00K | – | -$0.14 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 27, 2026before the open | – | – | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 13, 2025after the close | – | – | -$0.69 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 7, 2025before the open | – | – | – | Release |
| Q1 FY2025ended Mar 31, 2025 | Apr 28, 2025before the open | – | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 20, 2025after the close | – | – | -$0.67 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 14, 2024after the close | – | – | -$6.31 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 13, 2024after the close | – | – | -$2.45 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 9, 2024after the close | – | – | -$0.26 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 21, 2024after the close | – | – | -$0.42 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 13, 2023after the close | $338.00K | -80.9% | -$0.34 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 11, 2023before the open | $937.00K | -31.0% | -$0.42 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 9, 2023after the close | $1.29M | – | -$0.42 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 22, 2023after the close | $59.00K | – | -$0.42 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 10, 2022after the close | $1.77M | – | -$0.38 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 15, 2022after the close | $1.36M | – | -$0.86 | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Senti Biosciences has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Senti Biosciences puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Senti Biosciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Update
- Update
- Results
- Results
- Update
- Update
- Results
- Results
- Results
- Results
See a number that looks wrong?